source
- GSK agrees $1.3 billion deal with Hutchmed for early-stage KRAS-EGFR cancer candidateGSK will pay $110 million upfront to Hutchmed as part of a deal that could reach $1.295 billion, giving GSK worldwide rights to develop and commercialize a preclinical oncology asset. The asset, i…
- B. Braun recalls three lots of 0.9% Sodium Chloride injection due to zinc oxide particlesB. Braun Medical Inc announced a voluntary recall of three lots of its 0.9% Sodium Chloride Injection USP, 100 mL, packaged in a 150 mL PAB® container. The recall was triggered after testing ident…